Molecular Engineering of Somatostatin Analogue with Minimal Dipeptide Motif Induces the Formation of Functional Nanoparticles
Source abstract
Abstract
Abstract Functionalized nanoparticles decorated with functional biological entities serve as preferred vehicles for numerous theranostic applications. Here we offer an alternative strategy in which the targeting moieties also act as building blocks for the formation of functional nanoassemblies. Diphenylalanine, a small, highly potent self‐assembling module, was incorporated with a somatostatin analogue, a modified hormone which preferentially binds to cancer cells. The co‐assembly of the engineered hormone together with the structurally diverse diphenylalanine derivative allowed the formation of bioactive homogenous spherical nanostructures. Significant internalization capacity of the loaded co‐assembled nanospheres into cancer cells in vitro, as well as selective in vivo accumulation in tumors, were demonstrated. These findings present a new method for the molecular engineering of bioactive peptide molecules by minor modifications with a remarkably potent association motif.
Source: crossref · Quality: baseline
Research context
OpenAlex topics: Supramolecular Self-Assembly in Materials · Chemical Synthesis and Analysis · Supramolecular Chemistry and Complexes
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
Department of Molecular Microbiology and Biotechnology George S. Wise Faculty of Life Sciences Tel Aviv University Tel Aviv 69978 Israel
Advanced Technology Center Sheba Medical Center Tel Hashomer 52621 Israel
Department of Materials Science and Engineering Iby and Aladar Fleischman Faculty of Engineering Tel Aviv University Tel Aviv 69978 Israel
Department of Oral Biology The Goldschleger School of Dental Medicine Sackler Faculty of Medicine Tel Aviv University Tel Aviv 69978 Israel
References (43)
Show source-provided references
1.
2. 10.1038/366324a010.1038/366324a0 ↗
3. 10.1002/bip.2132810.1002/bip.21328 ↗
4. 10.1166/jnn.2007.64510.1166/jnn.2007.645 ↗
5.
6. 10.1126/science.108238710.1126/science.1082387 ↗
7. 10.1039/b915765b10.1039/b915765b ↗
8. 10.1039/C4CS00164H10.1039/C4CS00164H ↗
9.
10. 10.1002/chem.20080001210.1002/chem.200800012 ↗
11. 10.1038/ncomms621910.1038/ncomms6219 ↗
12. 10.1038/nchem.212210.1038/nchem.2122 ↗
13.
14. 10.1021/nn302983e10.1021/nn302983e ↗
15. 10.1111/jmi.1200510.1111/jmi.12005 ↗
16. 10.1021/bm900584m10.1021/bm900584m ↗
17.
18. 10.1002/adma.20050176510.1002/adma.200501765 ↗
19. 10.1002/adma.20050152210.1002/adma.200501522 ↗
20. 10.1002/adma.20070122110.1002/adma.200701221 ↗
21. 10.1039/B916738B10.1039/B916738B ↗
22. 10.1039/c1sm05034f10.1039/c1sm05034f ↗
23. 10.1016/j.biomaterials.2009.01.01010.1016/j.biomaterials.2009.01.010 ↗
24. 10.1038/nbt87410.1038/nbt874 ↗
25. Matsumura Y. · Cancer Res. · 1986 · 46 · 6387
26. 10.1021/nn900002m10.1021/nn900002m ↗
27.
28. 10.1126/science.179.4068.7710.1126/science.179.4068.77 ↗
29. 10.1056/NEJM19831215309240610.1056/NEJM198312153092406 ↗
30. 10.1006/frne.1999.018310.1006/frne.1999.0183 ↗
31.
32. 10.1016/0960-0760(92)90184-K10.1016/0960-0760(92)90184-K ↗
33. Reubi J. C. · Yale J. Biol. Med. · 1997 · 70 · 471
34. 10.1016/j.lungcan.2005.07.00910.1016/j.lungcan.2005.07.009 ↗
35.
36. Keskin O. · OncoTargets Ther. · 2013 · 6 · 471
37. 10.1155/2013/92629510.1155/2013/926295 ↗
38.
39. 10.1560/5MC0-V3DX-KE0B-YF3J10.1560/5MC0-V3DX-KE0B-YF3J ↗
40. 10.1088/1478-3975/3/1/S0210.1088/1478-3975/3/1/S02 ↗
41. 10.1002/chem.20110036210.1002/chem.201100362 ↗
42. 10.1002/psc.241110.1002/psc.2411 ↗
43. 10.1021/cr03069810.1021/cr030698 ↗